synthesis molecular character new isatinbas hydrazonoindolinon ao ae report vitro antiprolif potent synths compound examine ht colon zr breast lung human cancer cell line b e active conger test average ic value Î¼m respect compare refer drug sunitinib exhibit value compound select pharmacology value order gain insight possible meghan action increase caps active fold h treatment caps decrease percentage cell g phase cycle correspond increase phase admit phosphorus tyrosine ptr level nearly twofold appear load plea microspher prepare use modify emulsionsolv diffs method encapsul office release profil character slow continue day curve fit zero kinen incorpor improv toward line incur period le 